PropThink: New Patents Further Vascepa's Intellectual Property Protection
(Thomson Reuters ONE) -
By Jake King
Amarin Corp. (NASDAQ:AMRN) got a bump in the pre-market Tuesday after announcing
that two more patents have been added to Vascepa's Intellectual Property,
protecting the franchise out to 2030. Patents 8,793,727 and 8,293,728 speak to
methods of use for icosapent ethyl, Vascepa's chemical name, and relate to the
former patent applications 12/702,889 and 13/349,153. Independent patent
attorneys analyzing the applications deemed the '889 application among the
strongest pieces of intellectual property surrounding Vascepa. The news should
give investors, analysts, and more importantly, Amarin's potential suitors,
confidence that New Chemical Entity status is less important than the market may
be assuming. The patent issuance lends exclusivity to icosapent ethyl for the
treatment of hypertriglyceridemia, or high triglycerides, and leaves no pathway
for generic companies to get around these patents without challenging the
patents' validity or enforceability directly, which we see as a very low-
probability prospect.
Amarin is listing the patents in the FDA's Orange Book, adding to Vascepa's
overall patent estate and making them part of the broader portfolio that generic
drug makers would be required to challenge under Hatch-Waxman statues (common
generic laws). Investors interested in the Amarin story may be better served
with an options strategy, allowing for a hedge against major swings that could
accompany a New Chemical Entity decision, a buy-out, or the company moving to
launch Vascepa on its own. Expect AMRN to trade higher Tuesday on the new patent
issuance.
See This Story at PropThink.com
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at http://www.propthink.com.
Disclaimer:
You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at http://www.propthink.com/disclaimer.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1651561]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Ridgeline Announces Oil Recovery Capacity SaleDatum: 23.10.2012 - 15:04 Uhr
Sprache: Deutsch
News-ID 195317
Anzahl Zeichen: 3953
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: New Patents Further Vascepa's Intellectual Property Protection"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
